Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for primary membranous nephropathy
ChiCTR2300077036Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of telitacicept in idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Change in 24-hour proteinuria from baseline at week 24. Started Mar 2023; status: recruiting.
02
Drugs
telitacicept
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2300077036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077036.